acute

Dade Behrings (hsCRP) Tests and BNTM Series Analyzers

... by the liver during systemic infection, and is an acute inflammatory marker. While CRP testing has been around for many years, it has only been recently that tests sensitive enough to measure the mildly elevated levels that occur with CHD have been developed. Dade Behring is the developer and manufacturer...

Rapid Whole Blood Testing for Infectious Mononucleosis Antibodies

...c infections, compromised respiration secondary to acute lymphadenopathy, anemia and ruptured spleen. Therefore, accurate diagnosis and prompt treatment of complications is important. Differential diagnosis of IM is also useful in ruling out other mononucleosis-like illnesses induced by cytomegalovirus, ad...

Point of Care Cardiac Analyzers Yield Rapid Cardiac Marker Results

...nce of cardiac markers in diagnosing or ruling out acute myocardial infarction. The measurement of cardiac... in the large fraction of patients presenting with acute coronary syndrome (ACS) who have negative 12-lead EKGs. About 30% of patients previously considered...

West Nile Virus Screening and Diagnostics Technology Emerges In Step with North American Outbreak

...invasive WNV disease (meningitis, encephalitis, or acute flaccid paralysis) among persons in the United States. ArboNet has also recorded 629 deaths. Serologic surveys indicate that symptoms develop in approximately 20 percent of infected people and that neuroinvasive disease occurs in 1 in 140. The ri...

Tight Glycemic Control in the ICU

...rcent. It also greatly decreased the incidence of acute renal failure, septicemia, and critical illness polyneuropathy. While there is ongoing debate and research on what level of blood glucose is optimal, and whether the benefits to patients result solely from lower blood glucose, or from the broad physi...

New Point-of-Care Methods to Measure Coronary and Cerebrovascular Risk

...ufficient blood supply to end organs, which may be acute or chronic. Despite the central role of the artery in coronary and cerebrovascular disease, it has not been practical to screen every patient by directly assessing the arteries. Direct assays such as carotid ultrasound, coronary angiography, compute...

Near-Patient Testing: The Advantages of C-Reactive Protein in Hematological Testing

...uides numerous therapeutic interventions. CRP, an acute phase plasma protein, is involved in the innate inflammatory response and is a well known marker of systemic inflammation. CRP is secreted rapidly, within a few hours of the immunological insult, upon activation by specific cytokines. CRP is, theref...

Sygnis Pharma AG announces date for presentation of clinical results

...tudy is to show safety and tolerability ofAX200 in acute stroke patients. The results of the AXIS-study are... develops compounds that protect nerve cells inthe acute phase of the disease, and beyond that, also stimulate theregeneration of the damaged nervous system....

Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis

...l treatmentgroups. In addition, treatment emergent acute coronary syndrome(ACS) events were infrequent and similar across treatmentgroups. Results from the European knee replacement trial (RE-MODEL) werepreviously presented in December 2006 (iii) at the Annual Meetingof the American Society of Hematology....

Positive Aggrastat Results Featured in the Journal of the American College of Cardiology

...f the cumulative incidence of death,MI, and TVR in acute myocardial infarction patients. The resultsfrom MU...ion with heparin, is indicated for thetreatment of acute coronary syndrome, including patients who are tobe medically managed and those undergoing percutaneo...

YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial

...ated inhalation of AeroLEF(TM)for the treatment of acute post-operative pain following orthopedicsurgery. The first phase of the study (Part 1) was a 21 patientopen-label, lead-in phase to ensure consistency of AeroLEF(TM)administration across study sites. Results of Part I of the PhaseIIb study were prese...

New Information on the Potential of Plasmin Shared at ISTH Congress

...of Plasmin as a potential newthrombolytic to treat acute clotting disorders, such as peripheralarterial occ...to provide improvements whentreating patients with acute clotting disorders," said VictorMarder, M.D., Chairman, David Geffen School of Medicine atUniversity...

Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis

...entand commercialization of novel therapeutics for acute and chroniccardiovascular and vascular disease. Portola is currentlydeveloping two clinical stage antithrombotics. Portola's leadcompound, PRT054021, is an oral Factor Xa inhibitor for theprevention of venous thromboembolism after orthopedic surgery,...

CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa

...gina and diabetes)and MERLIN TIMI-36 (n=2,220 with acute coronary syndromes anddiabetes) clinical trials. In CARISA (Combination Assessment of Ranolazine in StableAngina), Ranexa (ranolazine extended release tablets) reduced HbA1clevels by an average of up to 0.7 percentage points in anginapatients with d...

Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting System's Success in Mouse Model Reported in Cancer Cell

...inistered," Hung says. Theteam looked for signs of acute systemic toxicity and ofpancreatitis, a dangerous ...roduces virtually no systemically acutetoxicity or acute pancreatitis." Abbruzzese says any clinical trial will advance under a NationalCancer Institute Spe...

International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis

...e than 60,000 patients who weresurveyed across 358 acute care hospitals randomly selected in 32countries, e...SE were to assess the prevalence ofVTE risk in the acute hospital care setting and to determine theproportion of at-risk patients who receive recommended pro...

AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis

...y shownpositive results in trials for treatment of acute renal failure andsepsis. Bart Wuurman, CEO commen... fortwo products; Alkaline Phosphatase for sepsis, acute renal failureand ulcerative colitis; and Anti-microbial Peptide hLF1-11 for theprevention of infecti...

Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery

...t forthe prevention and treatment of thrombosis in acute and chronicsettings, enabling convenient administr... fibrillation at risk forstroke; those at risk for acute myocardial infarction (heartattack); those undergoing orthopaedic surgery at risk fordeveloping DVT ...

New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility

...story of VTE or diagnosis of cancer and predefined acute medicalillness were randomized to received enoxapa...in venous andarterial vessels to prevent potential acute or chroniccomplications of venous or arterial thrombosis. As with allanticoagulants, the most freque...

Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery

...tfor the prevention and treatment of thrombosis in acute and chronicsettings, enabling convenient administration in both the hospitaland at home. Rivaroxaban is being jointly developed by Johnson & JohnsonPharmaceutical Research & Development L.L.C. (J&JPRD), andBayer HealthCare AG. Lead RECO...

Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis

... anticoagulant protein c2(rNAPc2) in patients with acute coronary syndromes (ACS),preclinical data evaluati...evelopment and commercializationof novel drugs for acute cardiovascular and cancer therapy.Nuvelo's development pipeline includes three acute cardiovascularp...

Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)

... canreduce the risk of thrombosis in patients with acute coronarysyndrome. The Phase I study in healthy volunteers is designed to assesssafety, tolerability and pharmacokinetics of ALX-0081. It will alsoanalyse pharmacodynamic effects of ALX-0081 to confirm its highpotency. It is a double-blind, placebo-c...

Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)

...gh immediate, high-level platelet inhibitionin the acute setting and a seamless transition to predictable,r...entand commercialization of novel therapeutics for acute and chroniccardiovascular and vascular disease. Portola is currentlydeveloping two clinical stage an...

Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival

... ejection fraction. There have beenrare reports of acute diffuse infiltrative pulmonary disease ofunknown e...itored during treatmentwith VELCADE. Rare cases of acute liver failure have been reportedin patients receiving multiple concomitant medications and withserio...

New Study in Journal of Pediatrics Suggests Synagis (Palivizumab) May Reduce Subsequent Recurrent Wheezing in Preterm Infants

...chanical ventilation and intensive care. Beyondthe acute consequences of infection, epidemiologic data sugg...hylaxis and rare (<1per 1,000 patients) severe acute hypersensitivity reactions havebeen reported with Synagis. Cases of anaphylaxis were reportedfollowi...

Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma

... ejection fraction. There have beenrare reports of acute diffuse infiltrative pulmonary disease ofunknown e...itored during treatmentwith VELCADE. Rare cases of acute liver failure have been reportedin patients receiving multiple concomitant medications and withserio...

Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients

... ejection fraction. There have beenrare reports of acute diffuse infiltrative pulmonary disease ofunknown e...itored during treatmentwith VELCADE. Rare cases of acute liver failure have been reportedin patients receiving multiple concomitant medications and withserio...

CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP

...om related criteria. C-reactive protein(CRP) is an acute phase protein and marker of systemicinflammation. A relationship between inflammatory processes andelevation of CRP has been established in a number ofimmuno-inflammatory diseases, including RA. Conference Call Information CombinatoRx management wi...

Largest National U.S. Healthcare Facility MRSA Study Reveals Infection Rates Eight Times Greater Than Previous Estimates

...lities caring for virtually every type of patient: acute care,cancer, cardiac, pediatric, rehabilitation and long-term care, andincluded county, public and private facilities. The survey alsorepresents a cross-section of all sizes of facilities, from lessthan 100 to more than 300 bed facilities. This is...

Second Phase III Study Evaluating Gilead's Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint

...e warranted. Renal impairment, including cases of acute renal failure andFanconi syndrome, has been reported in association with the use ofViread. It is recommended that creatinine clearance be calculatedin all patients prior to initiating therapy with Viread and asclinically appropriate during therapy. C...

BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting

...vices and drugs to treat and possiblycure numerous acute and chronic diseases. Additionally, PAConsulting Group, a global consulting firm with expertise in lifesciences and healthcare, estimates the worldwide market for mediato preserve cells, tissues, and organs for research and clinical applications wil...

Second Phase III Study Evaluating Gilead's Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint

...e warranted. Renal impairment, including cases of acute renal failure andFanconi syndrome, has been reported in association with the use ofViread. It is recommended that creatinine clearance be calculatedin all patients prior to initiating therapy with Viread and asclinically appropriate during therapy. C...

Nationwide MRSA Prevalence Study to Demonstrate Full Scope of 'Superbug' Threat Facing U.S. Healthcare Facilities and Patients

...r virtually every type of patient, including acute care, cancer, cardiac, pediatric, rehabilitation and long-term care. -- The study, funded by the Association for Professionals in Infection Control and Epidemiology (APIC), collected data from more than 1,200 healthcare facilitie...

Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in Journal of American College of Cardiology

...and an early invasive approach fornon-ST-elevation acute coronary syndromes (NSTE-ACS). "In clinical studi...evelopment and commercialization of noveldrugs for acute cardiovascular and cancer therapy. Nuvelo'sdevelopment pipeline includes three acute cardiovascular ...

Vical Licensee AnGes MG Announces Positive Results of Phase 3 Angiogenesis Trial in Japan

...ral hematoma, prostatecancer, bladder perforation, acute renal failure, peritonitis,bacterial pneumonia). However, causality due to AMG0001 wasestimated none or low. In Placebo group, there were 4 SAEs in 3subjects (2 embolism, toe gangrene, pain in thigh). All SAEs out of all studies using AMG0001 were e...

Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop

... ejection fraction. There have beenrare reports of acute diffuse infiltrative pulmonary disease ofunknown e...itored during treatmentwith VELCADE. Rare cases of acute liver failure have been reportedin patients receiving multiple concomitant medications and withserio...

BioCryst Presents Phase I Peramivir Data at the Options for the Control of Influenza Conference

...s. About Influenza The influenza virus causes an acute viral disease of therespiratory tract. Unlike the common cold and some otherrespiratory infections, seasonal flu can cause severe illness,resulting in life-threatening complications. According to theCenters for Disease Control and Prevention, every y...

Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Geron's Human Embryonic Stem Cell-Based Therapeutic for Heart Failure

... hESC-derived oligodendroglialprogenitor cells for acute spinal cord injury, the functionalcharacterization...nent. With our most advanced cell type,GRNOPC1 for acute spinal cord injury, we remain on track for thefiling of an Investigational New Drug (IND) Applicatio...

Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure Reduction During Important Early Morning Period When Most Adverse Cardiovascular Events Occur

...scular events. Each year in theUnited States alone acute myocardial infarction develops in over600,000 persons who were previously free of cardiac symptoms. Alarge study has revealed a marked circadian periodicity in theonset of myocardial infarction with the primary peak incidencebeing in the morning. At ...

Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care

...eastcancer, and is in addition being developed for acute radiationinjury. NOV-205 acts as a hepatoprotective agent withimmunomodulating and anti-inflammatory properties. NOV-205 is inPhase 1b development for chronic hepatitis C non-responders. Bothcompounds have completed clinical trials in humans and have...

New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines

... clinicaltrials, and a lead oncology compound (for acute myeloid leukemia,or AML) with demonstrated efficacy in a Phase III trial; amarketing authorization application for this compound is underreview by the European Agency for the Evaluation of MedicinalProducts (EMEA). EpiCept is based in Tarrytown, N.Y....

Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy

...irst infusion of ORENCIA in Period C.There was one acute infusion reaction (palpebral edema, pruritusand rash) later during Period C. No deaths or malignant neoplasmswere reported during this Period. The overall safety profile afterre-establishing therapy with ORENCIA was similar to that observedin patient...

Barrier Therapeutics Announces Liarozole Phase 2/3 Study Results in Lamellar Ichthyosis

...nychomycosis, psoriasis, acne, skin allergies, and acute fungalinfections. The company is headquartered in Princeton, New Jerseyand has wholly owned subsidiaries in Geel, Belgium and Ontario,Canada. More information about Barrier Therapeutics can be found onits corporate website at: www.barriertherapeutics...

Critical Therapeutics Announces the Publication of Data for ZyfloCR (Zileuton) Extended-Release Tablets in the Journal of Asthma

...n acuteasthma attacks, but can be continued during acute exacerbations ofasthma. The study, titled "The Saf...ndicated for use in the reversal of bronchospasmin acute asthma attacks. Therapy with ZYFLO CR and ZYFLO can becontinued during acute exacerbations of asthma...

July Issue of Journal of Antimicrobial Chemotherapy Highlights Study of Factive Tablets for Five-Day Treatment of Community-Acquired Pneumonia

...the U.S. for thefive-day treatment of both CAP and acute bacterial exacerbations ofchronic bronchitis (AECB... is an antibioticFDA-approved for the treatment of acute bacterial exacerbations ofchronic bronchitis and community-acquired pneumonia of mild tomoderate sev...

Gabapentin Shown Effective for Fibromyalgia Pain

... Although gabapentin has little, if any, effect on acute pain, ithas shown a robust effect on pain caused by a heightened responseto stimuli related to inflammation or nerve injury in animal modelsof chronic pain syndromes. Researchers have suspected that it mighthave the same effect in people with fibromy...

Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine

...Women in the study had responded poorly toprevious acute triptan treatment for MM. "In this study, appro...nformation about FROVA FROVA is indicated for the acute treatment of migraine attackswith or without aura in adults. FROVA is not intended for theprophylact...

Sunesis Pharmaceuticals Reports Positive Data From Studies of Two Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of the European Hematology Association

...time results in diseaseremissions in patients with acute leukemias," said Daniel C.Adelman, M.D., Sunesis' ... astudy population with relapsed and/or refractory acute leukemias,we expect that SNS-595 will continue to show positive evidence ofclinically meaningful act...

Vion Pharmaceuticals Presents Clinical Data from a Phase II Trial of Cloretazine (VNP40101M) in Elderly AML Patients with Unfavorable Cytogenetics at EHA Meeting

...clinical trial in a subset ofelderly patients with acute myelogenous leukemia (AML) or high-riskmyelodyspla...atients with previouslyuntreated de novo poor-risk acute myelogenous leukemia. Anadditional trial of Cloretazine(R) (VNP40101M) as a single agent insmall cel...

Pilot Phase 3 Results of NovaCardia's KW-3902 for Acute Congestive Heart Failure Presented at Late-Breaking Session of Heart Failure Congress 2007

...t in development for thetreatment of patients with acute congestive heart failure (CHF),that indicate a str...the pilot Phase 3trial. Hospitalized patients with acute CHF with renal impairment,which was defined as having creatinine clearance of 20 to 80milliliters pe...

NuPathe Reports Positive Phase One Results for NP101 Transdermal Therapy for Acute Migraine

...I study of NP101SmartRelief, a novel treatment for acute migraine being developedby NuPathe. NP101 combines...matriptan, the mostwidely prescribed treatment for acute migraine in the UnitedStates. Sumatriptan is also the active ingredient in IMITREX(R),which is also ...

Archemix Announces Completion of Phase 1 Trial of ARC1779

...9 to evaluatethe safety and efficacy of ARC1779 in acute coronary syndromepatients during the fourth quarte...of aptamer therapeutics with aproprietary focus in acute cardiovascular and hematologicaldiseases," commented Errol De Souza, Ph.D., President and ChiefExecu...

Phase III Study Evaluating Gilead's Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint

...e warranted. Renal impairment, including cases of acute renal failure andFanconi syndrome, has been reported in association with the use ofViread. It is recommended that creatinine clearance be calculatedin all patients prior to initiating therapy with Viread and asclinically appropriate during therapy. C...

Archimedes Pharma Presents Positive Efficacy and Safety Data on Nasalfent at European Association for Palliative Care Congress

...mptoms of malnutrition especially in patients with acute alcoholproblems. Archimedes' strategy is to grow its commercial presenceorganically and through the acquisition of pharmaceutical companiesor marketed brands in Europe and through partnering or licensing ofEuropean rights to new specialist prescribe...

Merck's Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study

... medicine in Phase III clinical developmentfor the acute treatment of migraine in adults and, if approved, ...strate thetherapeutic potential of MK-0974 for the acute treatment ofmigraines," said Tony Ho, M.D., senior director of ClinicalNeuroscience, Merck Research ...

Roxro Pharma’s Novel Intranasal Pain Reliever Effective, Well Tolerated in Phase 3 Study

...intranasal analgesic indicated forthe treatment of acute pain. "We are eager to bring a novel paintreatment... promisingdrug candidates for rapid development in acute pain conditions. Thecompany’s highly experienced staff engages a global networkof external exp...

Alexza Pharmaceuticals to Present AZ-004 (Staccato Loxapine) Clinical Data at the Annual NCDEU Meeting

...004), which is being developed forthe treatment of acute agitation in patients with schizophrenia.The annua...of novel,proprietary products for the treatment of acute and intermittentconditions. The Company's technology, the Staccato system,vaporizes unformulated dru...

MGI Pharma Summarizes Data Presented at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting

...abiopharmaceutical company focused in oncology and acute care, todayprovided highlights of data presentatio...) and activity observed in patientswith refractory acute lymphocytic leukemia (ALL). Gliadel(R) Wafer(polifeprosan 20 with carmustine implant) was the subjec...

Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors

...ority of patients, while transformation fromMDS to acute myelogenous leukemia (AML) occurs in up to 40 perc...f leukemia cellproliferation in some patients with acute myelogenous leukemia(AML). XL999 exhibited potent activity in preclinicaltarget-specific pharmacodyn...

MGI Pharma, Inc. Summarizes Data Presented at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting

...resentation of efficacy data in olderpatients with acute myelogenous leukemia (AML) and activityobserved in patients with refractory acute lymphocytic leukemia(ALL). Gliadel Wafer (polifeprosan 20 with carmustine implant) wasthe subject of...